Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (HEK293)

DMF
製品番号/仕様
価格
Availability
数量
FM3-Y45P1-25tests
$345.00
In Stock - Delivery in 2-3 business days
FM3-Y45P1-250tests
$2,345.00
In Stock - Delivery in 2-3 business days
FM3-Y45P1-1000tests
$8,170.00
In Stock - Delivery in 2-3 business days
FM3-Y45P1
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (HEK293) is a neutralizing mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.

Antibody Type

Recombinant Monoclonal

Clone

Y45

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Reactivity

Mouse

Immunogen

Recombinant FMC63 scFv derived from HEK293 cells

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).

Recommended Dilution

1:50

Isotype Control

The isotype control is sold separately; please refer to Cat. No. DNP-M1A1 for product information.

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.5% BSA, with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 24 months in lyophilized state;
  • -70°C for 12 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.